Drug Trial Radar · NCT04982224
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
30
Actual
Start
Nov 9, 2021
Primary completion
Oct 15, 2025
Study completion Oct 15, 2025
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jul 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN5093-M114 by itself and in combination with cemiplimab. The study is focused on advanced non-small cell lung cancer (NSCLC) that produces too much of a protein called mesenchymal epithelial transition factor (MET) on the cancer cell surface. The aim of the study is to see how safe, tolerable, and effective the study drug is. This study will include 3 study groups, or cohorts, and each group is split into 2 parts: Part 1: The main purpose of part 1 is to determine a safe dose of REGN5093-M114 (Cohorts A and B), and in combination with cemiplimab (Cohort C). Part 2: The main purpose of part 2 is to use the REGN5093-M114 dose found for each cohort in part 1 to see how well the study drug works to shrink tumors. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug * Does the study drug work to reduce or delay the progression of your cancer * How much study drug is in the blood at different times * Does the body make antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions
- Advanced NSCLC
Interventions
REGN5093-M114Drug
Administered by intravenous (IV) infusion
CemiplimabDrug
Administered by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities (DLTs)Time frame: Up to 28 days
- Treatment-emergent adverse events (TEAEs)Time frame: Through study completion, an average of 2 years
- Serious adverse events (SAEs)Time frame: Through study completion, an average of 2 years
- TEAEs leading to study treatment discontinuationTime frame: Through study completion, an average of 2 years
- TEAEs leading to deathTime frame: Through study completion, an average of 2 years
- Laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE])Time frame: Through study completion, an average of 2 years
- Concentrations of REGN5093-M114 in serumTime frame: Through study completion, an average of 2 years
- Total monoclonal antibodies (REGN5093- M114 plus unconjugated antibody) in serumTime frame: Through study completion, an average of 2 years
- Concentrations of M24 in plasmaTime frame: Through study completion, an average of 2 years
- Concentrations of cemiplimab when given in combination with REGN5093-M114Time frame: Through study completion, an average of 2 years
- Objective response rate (ORR)Time frame: Through study completion, an average of 2 years
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
University of California Irvine School of Medicine - Suite 400, Room 407
Orange, California
University of Colorado Hospital Anshutz Outpatient Pavillion
Denver, Colorado
Johns Hopkins Hospital - Clinical Study Location - Skip Viragh Outpatient Cancer Building
Baltimore, Maryland
Sidney Kimmel Comprehensive Cancer Center - 4F Second Medical Building
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
Henry Ford Hospital, Henry Ford Cancer Institute
Detroit, Michigan
Memorial Sloan Kettering Cancer Center
New York, New York
University of Pittsburgh Medical Center - Hillman Cancer Center
Pittsburgh, Pennsylvania
MUSC Hollings Cancer Center
Charleston, South Carolina
The University of Texas MD Anderson Cancer Center
Houston, Texas
Next Virginia
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.